The Journal of Vascular Anomalies (JOVA) is an international peer reviewed open access journal dedicated to the discovery and report of the scientific investigation, diagnosis, and treatment of congenital and acquired human vascular lesions. This contemporary journal aims to provide up-to-date information on vascular anomalies from a broad array of medical, surgical, radiologic and scientific disciplines. Such disciplines include, but not limited to, dermatology, plastic surgery, interventional radiology, otolaryngology, pathology, hematology/oncology, genetics, and laboratory sciences.
In line with its parent organization, the International Society for the Study of Vascular Anomalies (ISSVA), JOVA aims to publish high quality and broadly impactful articles in the spirit of a multidisciplinary approach to understanding and treating vascular disorders. As and open access journal, JOVA desires to inform and educate a global audience on novel approaches, evidence based research, critical reviews and emerging science. Manuscript submissions are open to all physicians, researchers, and health care providers in the space of clinical and biologic vascular sciences. Contributions will include papers and posters presented at the International ISSVA workshops.
Gresham T. Richter, MD, FACS, FAAP
Dr. Gresham Richter became the first editor in chief of the Journal of Vascular Anomalies in 2020 through unanimous election by the Board of the International Society for Study of Vascular Anomalies (ISSVA). He was born in Colorado (U.S.A) and received his undergraduate and medical degrees from the same state at the University of Colorado and University of Colorado for Health Sciences. He completed his residency in Otolaryngology-Head and Neck Surgery at the University of Arkansas for Medical Sciences (UAMS) and fellowship in Pediatric Otolaryngology at Cincinnati Children's Hospital. He returned to Arkansas to join the UAMS faculty and Arkansas Children's Hospital where he founded the Arkansas Vascular Biology Program, a robust clinic and laboratory dedicated to understanding and discovering new therapies for complex vascular lesions.
Dr. Richter went on to serve as Professor and Vice Chairman of the Department of Otolaryngology, Director of the Vascular Anomalies Center of Excellence, and Chief of Pediatric Otolaryngology. In this capacity he has received numerous grants and published broadly in vascular anomalies and head and neck surgery. He has authored 2 books, over 35 book chapters and over 100 peer reviewed manuscripts. He subsequently became the recipient of the Benjamin and Milton Waner Endowed Chair in Pediatric Facial Plastics and Reconstructive Surgery and the Hamlen and Siebert Endowed Chair in Pediatric Otolaryngology. Dr. Richter has received numerous clinical and research awards including many years of recognition for Best Doctor's in America. He maintains a very busy clinical practice in vascular anomalies and pediatric otolaryngology.
Contact details for submission
All manuscripts must be submitted online at www.editorialmanager.com/jova
Questions may be directed to the Editorial Office at [email protected].
Editorial review: JOVA Editor-in-Chief, a group of international Deputy Editors and international members of the ISSVA Editorial Board.
Conditions for submission
- Assures that the manuscript is an original work that has not been previously published
- Assures that the manuscript is not under consideration by any other publication
- Accepts full responsibility for the accuracy of all content, including findings, citations, quotations, and references contained within the manuscript
- Discloses on the title page and in the acknowledgment section any conflicts of interest related to the research or the manuscript
- Discloses on the title page all sources of funding, including a statement of no funding if applicable
- Discloses on the title page any previous presentation of the research, manuscript, or abstract
- Assures that authorship has been granted only to those individuals who have contributed substantially to the research or manuscript
- Discloses in the methods section of the manuscript that any investigation involving human subjects or the use of patient data for research purposes was approved by the committee on research ethics at the institution in which the research was conducted in accordance with the Declaration of the World Medical Association (www.wma.net) and that any informed consent from human subjects was obtained as required
- Attaches documents showing all relevant permissions to publish quotations, text, tables, or illustrations from copyrighted sources
- Discloses in the manuscript references and/or table/figure footnotes the full citation and permission of the copyright owner as required
The journal will only consider publication of work that includes information that is sufficient to permit replication by other laboratories. Manuscripts reporting data from novel chemical probes will not be considered unless the structure and pharmacological characterization, including selectivity and relevant formulation, are reported or directly described in a prior peer-reviewed publication.
*Authors' role: JOVA abides by the Authorship Criteria as set by the International Committee of Medical Journal Editors (ICMJE). Please visit http://www.icmje.org/index.html to review the criteria and determine whether contributors should be listed as authors or listed in the acknowledgements. Attributing authorship to those who do not meet the requirements set forth by the ICMJE is not acceptable. Similarly, it is unacceptable to exclude individuals meeting the requirements for authorship. Each person listed as an author is expected to have participated in the preparation of the manuscript in a significant way. Although JOVA endorses the ICMJE authorship requirements, the Editorial Board is not in a position to adjudicate disputed authorship issues. These must be resolved by the authors or by the institution responsible for the research. Should further guidance be needed, authors should consult the Committee on Publication Ethics (COPE) guidelines for authorship disputes.
Article processing charges: JOVA is an open access, peer-reviewed journal. To provide open access, the journal charges publication fees for each article published. These fees cover the expenses incurred by publication, including the peer-review process, journal production and publication, and hosting and archiving fees. Fees vary by article type. The APCs for JOVA are as shown below. ISSVA members pay a substantially discounted rate. Membership will be verified at acceptance.
| ||2020 ||2021 || 2022||2023 ||2024 |
|Full length basic science/clinical articles, reviews, guidelines, and consensus statements) (non-Members)||$1,200 || $1,250|| $1,300|| $1,300|| $ 1,390|
|Case reports/short communications. Editorials, and Letters to the Editor (all other article types except full length basic science/clinical articles)||$700 || $700|| $790|| $790|| $850|
|Full length basic science/clinical articles, reviews, guidelines, and consensus statements (Members)||$1,000 || $1,075|| $1,150|| $1,150|| $1,200|
The following article types are considered for publication:
- Original papers
- Scientific research (molecular, genetic, histologic) (maximum of 4,000 words)
- Clinical study (Prospective, Retrospective, Case Series) (maximum of 4,000 words)
- Contemporary review (maximum of 4,000 words)
- Evidence based review (maximum of 4,000 words)
- How I do it (maximum of 1,500 words)
- Case report (maximum of 1,500 words)
- Letter to the editor (maximum of 1,000 words)
Style: Pattern manuscript style after the American Medical Association Manual of Style (10th edition). Stedman's Medical Dictionary (27th edition) and Merriam Webster's Collegiate Dictionary (10th edition) should be used as standard references. Refer to drugs and therapeutic agents by their accepted generic or chemical names, and do not abbreviate them. Use code numbers only when a generic name is not yet available. In that case, supply the chemical name and a figure giving the chemical structure of the drug.
Capitalize the trade names of drugs and place them in parentheses after the generic names. To comply with trademark law, include the name and location (city, state when relevant, and country) of the manufacturer of any equipment mentioned in the manuscript. Use the metric system to express units of measure and degrees Celsius to express temperatures, and use SI units rather than conventional units.
Policies and procedures were adapted from or developed in conjunction with the guidelines provided by the Council of Science Editors (www.CouncilScienceEditors.org), including the CSE's white paper on promoting integrity in scientific journal publications, 2012 update.
Conflicts of interest
Conflicts of interest can be defined as conditions in which an individual holds conflicting or competing interests that could bias editorial decisions. Conflicts of interest may be only potential or perceived, or they may be actual. Personal, political, financial, or academic considerations can affect objectivity in numerous ways. Some specific types of conflict of interest include:
• Personal conflicts. Editors should avoid making decisions on manuscripts that conflict with their own interest, such as those submitted from their department or by research collaborators, co-authors (in the case of collaborators or co-authors, some time period should be established, such as "for the past five years"), competitors, or those addressing an issue in which they stand to gain financially (e.g., stock in a company whose product is discussed in the article). If they may have a perceived or actual conflict of interest, editors should delegate handling of any decision to other editors with decision-making responsibility. Editorials and/or opinion pieces are an exception to this rule.
• Financial conflicts. The most evident type of potential conflict of financial interest arises when an individual or organization may benefit financially from a decision to publish or to reject a manuscript. Financial conflicts may include salary, grants from a company with an interest in the results, honoraria, stock or equity interests, and intellectual property rights (patents, royalties, and copyrights).
• Nonfinancial conflicts. Other nonfinancial conflicts of interest should also be avoided or disclosed. Some of these include personal, political, academic, and religious conflicts.
Conflict of Interest Disclosure
JOVA will operate according to the standards established by the International Committee of Medical Journal Editors (ICMJE). Relevant documentation will be obtained from authors at manuscript submission (http://www.icmje.org/conflicts-of-interest/). Annual disclosure will also be obtained from everyone involved in the publication process: editors, editorial board members, editorial staff, and reviewers. The intent of disclosure is to promote informed decision about the existence and impact of potential conflicts of interest or bias, including the necessity for recusal or disqualification.
Financial support and competing interests: Disclosure information from all authors is handled within Editorial ManagerTM (EM) during the submission process. Upon initial submission, all co-authors are emailed a hyperlink via which they will verify their co-authorship and complete the Disclosure Form within EM.
In addition to completing the form, all authors must clearly state all relevant conflicts of interest in the unblinded title page. The name of each contributing author and any potential conflict of interest for each author for the previous 2 years should be listed. If no potential conflict exists, the phrase "No conflict" should appear after the author's name.
JOVA follows the Committee on Publication Ethics (COPE), which aims to define best practices in the ethics of publishing. A code of conduct has been established https://publicationethics.org/ to guide editors and editorial process.
Originality and validity of manuscript: A submitted manuscript must not have been previously published (except as an abstract) or be under consideration for publication elsewhere and, if accepted, may not be published elsewhere in a similar form, in any language, without the consent of the authors and the Orthopaedic Trauma Association.
Although the editors and referees make every effort to ensure the validity of published manuscripts, the final responsibility rests with the authors, not with JOVA, its editors, or the publisher.
Changes to authorship: This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts: Before an accepted manuscript is published online, requests to add or remove an author or to rearrange the author names must be sent to the editorial office from the corresponding author of the accepted manuscript. This request must include the reason the name or names should be added, removed, or rearranged and written confirmation (email, fax, or letter) from all authors that they agree with the addition, removal, or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the editorial office to the corresponding author, who must follow the foregoing procedure. Note that (1) the editorial office will inform the journal editors of any such requests and (2) publication of the accepted manuscript is suspended until authorship has been agreed to. After the accepted manuscript is published online, any requests to add, delete, or rearrange author names will follow the same policies as noted above and result in a corrigendum.
Patient anonymity and informed consent: It is the author's responsibility to ensure that a patient's anonymity is carefully protected. For photographs or videos, the author must obtain written and signed permission from the patient if the patient would be recognizable. Authors must state in their manuscript that informed consent was sought and granted.
It is also the author's responsibility to verify that any experimental investigation with human subjects reported in the manuscript was performed with informed consent and following all the guidelines for experimental investigation with human subjects required by the institution(s) with which all the authors are affiliated.
Human and animal studies: All manuscripts reporting human research must contain a statement that an appropriate institutional review board approved the study. Authors must identify the name of the local review board in their manuscript.
All subjects or their surrogates must have signed informed consent forms if required by the review board. All manuscripts reporting animal studies must use protocols that conform to the NIH guidelines (Guide for the Care and Use of Laboratory Animals, NIH Publication 86-23). Descriptions of surgical procedures on animals should include the route of drug administration, generic drug name, and dose of anesthetic used. Paralytic agents are not acceptable alternatives to anesthetics.
Creative Commons' license: Open access articles will be freely available to read, download, and share from the time of publication. JOVA provides authors the choice of applying any of the Creative Commons 4.0 licenses defined below, to be determined after acceptance. As these are open access articles, copyright is retained by the author.
Attribution-Non-Commercial-No-Derivatives: CC BY-NC-ND
This license allows others to download your works and share it with others as long as they credit you, but they can't change the work in any way or use it commercially. This is the automatic license chosen for OTA International submissions, unless the authors elect for another license.
This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered.
Permissions: Authors must submit written permission from the copyright owner (usually the author) to use direct quotations, tables, or illustrations that have appeared in copyrighted form elsewhere, along with complete details about the source.
Clinical trials: Clinical trials are subject to all policies regarding human research. JOVA follows the World Health Organization's (WHO) definition of a clinical trial:
A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes [...] Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioral treatments, process-of-care changes, preventive care, etc.
All clinical trials must be registered at or before the time of first patient enrollment in any primary registry of the WHO International Clinical Trials Registry Platform (ICTRP) [www.who.int/ictrp/network/primary/en/index.html] or in ClinicalTrials.gov [www.clinicaltrials.gov/], which is a data provider to the WHO ICTRP.
Authors of manuscripts describing the results of clinical trials must adhere to the CONSORT reporting guidelines appropriate to their trial design, available on the CONSORT Statement website [www.consort-statement.org]. Authors must provide the registry name and registry number in the cover letter and methods section and provide a completed CONSORT checklist and flow diagram as a figure, both of which can be found at www.consort-statement.org.
Our policies for clinical trial submissions are designed to promote transparency and reproducibility and ensure the integrity of the reporting of patient-centered trials. Editors and reviewers should carefully review trial protocols and registration details and assess manuscripts according to CONSORT or other relevant guidelines. Please contact the editorial office with any questions.
PEER REVIEW PROCESS
The peer review process is handled entirely electronically. Peer reviewers are instructed to review the contents of the submission in a critical, unbiased, and timely fashion. They review all pieces of the submission, including the manuscript itself as well as videos, tables, and images. Submissions are reviewed by at least two peer reviewers.
The Editor-in-Chief is excluded from managing the peer review process for any manuscript that includes the Editor-in-Chief as an author. A Deputy Editor performs the necessary duties in these instances.
Authors may suggest reviewers for their manuscripts, but there is no guarantee that the Editor-in-Chief will select all or any of the selections to serve on the review panel.
JOVA currently utilizes the double-blind method of peer reviewing.
MANUSCRIPT PREPARATION AND SUBMISSION INSTRUCTIONS
JOVA accepts online submission of manuscripts through Editorial ManagerTM. The site contains instructions and advice on how to use the system, guidance on the creation/scanning and saving of electronic art, and supporting documentation.
All manuscripts must be submitted online via Editorial ManagerTM, at www.editorialmanager.com/otai.
If you have previously submitted a manuscript to JOVA, you already have an account in the system and can use your same login credentials. If you do not recall your credentials, click on Send Username/Password to have them emailed to you. If you have never submitted to JOVA, see the instructions for first-time users below.
First-time users: Please click the Register button on the Editorial Manager home page. Enter the requested information to complete your registration. Upon successful registration, an email containing your user name and password will be sent to you. Please be sure to enter your email address correctly; if an error has been made or an incorrect email address has been provided, you will not receive this notification.
Note: If you have already received an email containing your username and password, or if you are already registered, do not register again.
Authors: Click the Login button on the Editorial Manager home page, enter your Username and Password, and click on Author Login. Click on the Submit Manuscript link to begin the submission process. Be sure to prepare your manuscript according to the requirements in these author instructions. Following submission to the journal office, you will be able to track the progress of your manuscript through the system.
If you experience any problems with Editorial Manager or have any questions, please contact the Editorial Office by clicking on the Contact Us link in the navigation bar or by emailing [email protected].
A structured abstract of no more than 250 words must be included for all article types.
For clinical investigations with human subjects use the following headings: Objectives (the exact question addressed by the article), Design (randomized, prospective, etc.), Setting (the location and level of clinical care), Patients/Participants (the manner of selection and number of patients who enter and complete the study), Intervention (the exact treatment used), Main Outcome Measurements (the primary study measure as planned before data collection began), Results, and Conclusions.
For basic science studies include the following headings: Objectives, Methods, Results, and Conclusions.
For systematic reviews and meta-analyses include the following headings: Objectives, Data Sources (specify database, search methodology, languages covered, and time frame), Study Selection (criteria used to select articles for detailed review), Data Extraction (means of assessing quality, validity, and comparability of extracted data), Data Synthesis (statistical techniques used for analysis), and Conclusions.
License to Publish forms: Upon first revision, authors will be required to complete a License to Publish (LTP) form. Authors can also provide these at the original submission stage. LTP forms may be signed by the Corresponding Author on behalf of all authors. Authors retain copyright for all articles. Authors grant the journal a license to publish the article and identify itself as the original publisher.
Manuscripts will not pass to production without completed forms. LTP forms are available from the submission site homepage www.editorialmanager.com/otai
Compliance with NIH and other research funding agency accessibility requirements, even before JOVA applies for PMC indexing: A number of research funding agencies now require or request authors to submit the post-publication (the article after peer review and acceptance but not the final published article) to a repository that is accessible online by all without charge. As a service to our authors, Wolters Kluwer identifies to the National Library of Medicine (NLM) articles that require deposit and transmits the post-print of an article based on research funded in whole or in part by the National Institutes of Health, Howard Hughes Medical Institute, or other funding agencies to PubMed Central. The License to Publish provides the mechanism. ISSVA and its publishing partner Wolters Kluwer ensure that authors can fully comply with the public access requirements of major funding bodies worldwide.
A) Creating Digital Artwork
- Learn about the publication requirements for Digital Artwork: http://links.lww.com/ES/A42
- Create, scan, and save your artwork and compare your final figure to the Digital Artwork Guideline Checklist (below).
- Upload each figure to Editorial Manager in conjunction with your manuscript text and tables.
B) Digital Artwork Guideline Checklist
Before submitting your digital art:
- Artwork should be saved as TIFF, PDF, Word Doc, PPT, or EPS files.
- Artwork should be created in the actual size (or slightly larger) it will appear in the journal.
- Crop out any white or black space surrounding the image.
- Diagrams, drawings, graphs, and other line art must be vector or saved at a resolution of at least 1200 dpi. If the art is created in an MS Office program, convert to a hi-res PDF. If the PDF creation process is unfamiliar then submit the MS Office doc.
- Photographs, radiographs, and other halftone images must be saved at a resolution of at least 300 dpi.
- Photographs and radiographs with text must be saved as postscript or at a resolution of at least 600 dpi.
- Each figure must be saved and submitted as a separate file. Figures should not be embedded in the manuscript text file.
- Cite figures consecutively in your manuscript.
- Number figures in the figure legend in the order in which they are discussed.
- Upload figures consecutively to the Editorial Manager website and number figures consecutively in the Description box during upload.
Please do not include images within your manuscript MS Word document.
Color figures: There is no charge to authors for the publication of color figures in JOVA. All figures will appear online as submitted by the author whether in color or black and white.
Figure legends: Legends must be submitted for all figures. They should be brief and specific and appear on a separate manuscript page after the references. Each legend should begin with a brief statement that identifies the figure. (Examples: Magnetic resonance imaging, Case 1). Use scale markers in the image for electron micrographs and indicate the type of stain used for tissue.
Tables: All tables should be uploaded as separate attachments at submission, not included within the manuscript document. Do not upload images of tables. All tabular matter must be editable text in Word. An image of a table, such as a scan, is not acceptable for publication.
Supplemental Digital Content (SDC): Authors may submit Supplemental Digital Content to supplement the information provided in the manuscript. SDC may include the following types of content: text, tables, figures, references peripheral to information provided as SDC, audio, and video. SDC should be consecutively cited in the Main Body text of the submitted manuscript. SDC files will be available via URL(s) placed at the citation points within the article and are not copyedited by the publisher. They will be presented digitally as submitted. Note that Journal policies for manuscript submission relating to peer review, patient anonymity, ethics, financial disclosure, copyright, and permissions also apply to SDC. Authors should mask patients' eyes and remove patients' names from supplemental digital content unless they obtain written consent from the patients and submit them as supplemental files at the time of the manuscript submission.
Format, File Type and Size Requirements: SDC may be presented in any format (PDF is preferred), and should indicate the article title and first author for clarity. Supplemental content should include a sequential number if submitting more than one (1, 2, 3, etc.). Each SDC in the file should have a visual header in the following name format (e.g., "SDC, Figure 1"; "SDC, Materials and Methods") and a corresponding citation must appear consecutively in the Main Body text. Note that SDC is numbered separately from non-SDC material. If providing SDC figure(s), a figure legend should be included on the figure itself. When uploading SDC select "Supplemental Digital Content" as the file designation. For audio and video files, also include the author name, videographer, participants, length (minutes), and size (MB). Video files should be formatted with a 320x240 pixel minimum screen size. Supplemental videos should be submitted using .wmv, .mov, .flv, .qt, .mpg, .mpeg, .mp4 formats only. Videos should not exceed 10 minutes of runtime. Videos must include embedded audio narration in English. For each submission, the SDC file cannot exceed a total size of 10 MB.
For more information, please review Wolters Kluwer's requirements for submitting Supplemental Digital Content: http://links.lww.com/A142.
English language assistance: Authors who are not native speakers of English who submit manuscripts to international journals often receive negative comments from referees or editors about the use of English in their manuscripts, and these problems can contribute to a decision to reject a paper. To help reduce the possibility of such problems, we encourage such authors to consider using Wolters Kluwer Author Services (see below).
Wolters Kluwer Author Services
Wolters Kluwer, in partnership with Editage, offers a unique range of editorial services to help you prepare a submission-ready manuscript:
- Premium Editing: Intensive language and structural editing of academic papers to increase chances of journal acceptance.
- Advanced Editing: A complete language, grammar, and terminology check to give you a publication-ready manuscript.
- Translation with Editing: Write your paper in your native language and Wolters Kluwer Author Services will translate it into English, as well as edit it to ensure that it meets international publication standards.
- Plagiarism Check: Helps ensure that your manuscript contains no instances of unintentional plagiarism.
- Artwork Preparation: Save precious time and effort by ensuring that your artwork is viewed favorably by the journal without you having to incur the additional cost of purchasing special graphics software.
For more information regarding Wolters Kluwer Author Services, please visit http://wkauthorservices.editage.com.
*Note that the use of such a service is at the author's own expense and risk, and does not guarantee that the article will be accepted.
Page proofs: Electronic page proofs and corrections: Corresponding authors will receive electronic page proofs to check the copyedited and typeset article before publication. PDF files of the typeset pages and support documents (such as the reprint order form) will be sent to the corresponding author via email. Complete instructions will be provided with the e-mail for downloading the file and returning corrected pages to the publisher.
It is the author's responsibility to ensure that there are no errors in the proofs. Changes that have been made to conform to journal style should be allowed to stand if they do not alter meaning. Authors may be charged for alterations to the proofs beyond those required to correct errors or to answer queries. Electronic proofs must be checked carefully and corrections returned within 48 hours of receipt, as requested in the electronic cover letter accompanying the page proofs. Failure to do so may result in delayed publication.
Authors retain copyright: Authors retain the copyright to their articles. Authors grant Wolters Kluwer a license to publish the article and identify itself as the original publisher.
FAQ for open access: http://links.lww.com/LWW-ES/A48.
Journal Contact Information: XXXXXXX, Managing Editor, [email protected]